Parallax Volatility Advisers’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-5,000
| Closed | -$319K | – | 1797 |
|
|
2025
Q1 | $319K | Hold |
5,000
| – | – | ﹤0.01% | 1268 |
|
|
2024
Q4 | $608K | Hold |
5,000
| – | – | ﹤0.01% | 1464 |
|
|
2024
Q3 | $624K | Hold |
5,000
| – | – | ﹤0.01% | 1472 |
|
|
2024
Q2 | $790K | Sell |
5,000
-25,000
| -83% | -$3.21M | ﹤0.01% | 1323 |
|
|
2024
Q1 | $3.88M | Buy |
30,000
+24,000
| +400% | +$2.94M | 0.01% | 811 |
|
|
2023
Q4 | $579K | Hold |
6,000
| – | – | ﹤0.01% | 1564 |
|
|
2023
Q3 | $727K | Hold |
6,000
| – | – | ﹤0.01% | 1492 |
|
|
2023
Q2 | $687K | Sell |
6,000
-1,500
| -20% | -$193K | ﹤0.01% | 1545 |
|
|
2023
Q1 | $1.03M | Sell |
7,500
-74,300
| -91% | -$9.64M | ﹤0.01% | 1488 |
|
|
2022
Q4 | $10.6M | Buy |
81,800
+63,300
| +342% | +$7.34M | 0.02% | 749 |
|
|
2022
Q3 | $2.04M | Hold |
18,500
| – | – | ﹤0.01% | 1424 |
|
|
2022
Q2 | $1.39M | Hold |
18,500
| – | – | ﹤0.01% | 1512 |
|
|
2022
Q1 | $1.45M | Sell |
18,500
-41,500
| -69% | -$3.18M | ﹤0.01% | 1501 |
|
|
2021
Q4 | $5.4M | Buy |
60,000
+10,000
| +20% | +$855K | ﹤0.01% | 1156 |
|
|
2021
Q3 | $4.62M | Hold |
50,000
| – | – | ﹤0.01% | 1267 |
|
|
2021
Q2 | $3.89M | Buy |
50,000
+25,000
| +100% | +$1.9M | ﹤0.01% | 1351 |
|
|
2021
Q1 | $1.86M | Buy |
25,000
+21,200
| +558% | +$1.96M | ﹤0.01% | 1785 |
|
|
2020
Q4 | $646K | Sell |
3,800
-107,900
| -97% | -$16M | ﹤0.01% | 2376 |
|
|
2020
Q3 | $15.7M | Buy |
111,700
+85,400
| +325% | +$13M | 0.01% | 808 |
|
|
2020
Q2 | $4.21M | Buy |
26,300
+14,000
| +114% | +$1.91M | ﹤0.01% | 1143 |
|
|
2020
Q1 | $1.2M | Buy |
+12,300
| New | +$1.41M | ﹤0.01% | 1421 |
|
|
2019
Q2 | – | Sell |
-7,000
| Closed | -$834K | – | 3670 |
|
|
2019
Q1 | $834K | Buy |
+7,000
| New | +$900K | ﹤0.01% | 1345 |
|
|
2017
Q1 | – | Sell |
-400,000
| Closed | -$11M | – | 4587 |
|
|
2016
Q4 | $11M | Buy |
400,000
+64,800
| +19% | +$2.6M | 0.02% | 412 |
|
|
2016
Q3 | $20.6M | Buy |
+335,200
| New | +$10.1M | 0.04% | 273 |
|
|
2016
Q1 | – | Sell |
-15,000
| Closed | -$579K | – | 3607 |
|
|
2015
Q4 | $579K | Hold |
15,000
| – | – | ﹤0.01% | 1479 |
|
|
2015
Q3 | $482K | Hold |
15,000
| – | – | ﹤0.01% | 1549 |
|
|
2015
Q2 | $456K | Buy |
+15,000
| New | +$307K | ﹤0.01% | 1667 |
|
Other funds holding SRPT
RCM
EAM
Parallax Volatility Advisers's SRPT Position: Q1 2026 in Review
Parallax Volatility Advisers sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 85 shares — an estimated $1.83K sold.
Parallax Volatility Advisers first reported a position in SRPT in Q3 2016 and held it in 20 quarters. The position peaked at $4.45M in Q4 2020. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Parallax Volatility Advisers reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
- Parallax Volatility Advisers sold 85 Sarepta Therapeutics shares in Q1 2026, an estimated $1.83K.
- Parallax Volatility Advisers first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 20 quarters.
- Parallax Volatility Advisers's Sarepta Therapeutics position peaked at $4.45M in Q4 2020.
- 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.